Literature DB >> 12556557

Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells.

Annabel Strife1, David Wisniewski, Chongyuan Liu, Caryl L Lambek, Zbigniew Darzynkiewicz, Richard T Silver, Bayard Clarkson.   

Abstract

We previously reported that chronic myelogenous leukemia (CML) primitive granulocyte-monocyte (GM) progenitors have a greatly reduced requirement for kit ligand (KL) to achieve optimal growth with granulocyte colony-stimulating factor (G-CSF) + granulocyte-monocyte colony-stimulating factor (GM-CSF). Conversely, others have demonstrated that unlike normal, CML CD34+ progenitors can proliferate in response to KL as a sole stimulus. To address these seemingly paradoxical findings, we examined the growth responses of CML CD34+ GM progenitors to various cytokines with and without a potent inhibitor of Bcr-Abl tyrosine kinase activity, PD173955. The heightened growth responses of CML GM progenitors to KL alone and to G-CSF + GM-CSF were abrogated by 10 nM PD173955 while having no effect on normal GM progenitors. While normal GM progenitors exhibited the expected synergistic response when KL was added to G-CSF + GM-CSF, CML GM progenitors had a minimal response; however, some synergism was restored by 10 nM PD173955. Normal erythroid progenitors require the synergistic interaction between KL and a saturating amount of erythropoietin (EPO, 1 unit) for optimal growth. In contrast, CML erythroid progenitors had up to 50% of optimal growth in KL alone, and, only a subthreshold amount of EPO (0.1 unit) was needed with KL to achieve 85% of the optimal response; these heightened growth responses were largely abrogated by 10 nM PD173955. Thus, direct evidence is provided that constitutively activated Bcr-Abl kinase pathways in primitive CML progenitors cooperate with single growth factors producing a heightened growth response, and, in so doing, disrupt the normally required synergistic interactions between KL and other cytokines to achieve activation and optimal growth of primitive progenitors. Coupled with our previous findings that a larger than normal proportion of CML primitive progenitors are at a later stage of maturation, we propose that this disruption of normal synergistic responses leads to increased progenitor recruitment into a committed pool by a process of accelerated maturation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556557

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  6 in total

1.  gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site.

Authors:  Patrick C Fraering; Wenjuan Ye; Matthew J LaVoie; Beth L Ostaszewski; Dennis J Selkoe; Michael S Wolfe
Journal:  J Biol Chem       Date:  2005-10-19       Impact factor: 5.157

2.  KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Authors:  Amie S Corbin; Thomas O'Hare; Zhimin Gu; Ira L Kraft; Anna M Eiring; Jamshid S Khorashad; Anthony D Pomicter; Tian Y Zhang; Christopher A Eide; Paul W Manley; Jorge E Cortes; Brian J Druker; Michael W Deininger
Journal:  Cancer Res       Date:  2013-07-25       Impact factor: 12.701

3.  Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex.

Authors:  Marco Gabbianelli; Ugo Testa; Ornella Morsilli; Elvira Pelosi; Ernestina Saulle; Eleonora Petrucci; Germana Castelli; Serena Giovinazzi; Gualtiero Mariani; Micol E Fiori; Giuseppina Bonanno; Adriana Massa; Carlo M Croce; Laura Fontana; Cesare Peschle
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

4.  Gleevec inhibits beta-amyloid production but not Notch cleavage.

Authors:  William J Netzer; Fei Dou; Dongming Cai; Darren Veach; Stephanie Jean; Yueming Li; William G Bornmann; Bayard Clarkson; Huaxi Xu; Paul Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-01       Impact factor: 11.205

5.  Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities.

Authors:  M Affer; S Dao; C Liu; A B Olshen; Q Mo; A Viale; C L Lambek; T G Marr; B D Clarkson
Journal:  J Oncol       Date:  2011-02-23       Impact factor: 4.375

6.  Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.

Authors:  D Wisniewski; M Affer; J Willshire; B Clarkson
Journal:  Blood Cancer J       Date:  2011-09-30       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.